HU
Humacyte, Inc.
HUMAW · NASDAQ
$0.00 -99.09% (-$0.23)
1M -87.14%
Market Cap $2.53M
P/E Ratio -
Div. Yield -
ROE 938.20%
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.08x
P/S 1.19x
PEG N/A
Growth
49 /100
Stable Book val. growth 70.15%
Rev. growth 9.20%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 4,599.72%
Op. margin 5,240.78%
Gross margin 666.81%
Quality
0 /100
Poor Asset turnover 0.02x
ROA 70.05%
ROIC 89.17%
Debt
30 /100
High Current ratio 6.21x
Int. coverage -8.39x
Debt/Equity 2.12x
Stability
1 /100
Unstable EPS volatility 477.33%
Profitable years 0
Beta 2.43x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na HUMAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Laura E. Niklason
Employees
184
Headquarters
Durham
Nadcházející události
06 LIS
Earnings
Upcoming earnings report